What is the total value and structure of Sun Pharma's acquisition of Organon, and what key strategic benefits does Sun Pharma expect from this deal?

Sun Pharma is acquiring Organon for $11.75 billion in an all-cash transaction, purchasing all of Organon’s shares at $14 per share. The deal grants Sun Pharma access to Organon’s biosimilars arm, positioning it as the world’s seventh-largest biosimilar company, and establishes it as a top-three global player in women’s health.

How did Organon come to be an independent company before its acquisition by Sun Pharma?

Organon originated from Schering-Plough, which merged with Merck & Co in 2009; Merck later spun out Organon in 2021 specifically to house its biosimilars and women’s health products, making it an independent entity prior to Sun Pharma’s acquisition.

Sun Pharma to Buy Organon for More Than $11 Billion

Apr 28, 2026

Sun Pharmaceutical Industries agreed to acquire Organon for $11.75 billion, gaining access to its biosimilars portfolio and becoming a top-three global women's health company.

cen

2026-04-26

India's Sun Pharma to Buy Organon in $11.75 Billion All-Cash Deal

2026-04-28

Sun Pharma to Buy Organon for More Than $11 Billion

2026-06-20

Sun Pharma to acquire Innovcare Lifesciences for $28.7 million

2026-07-29

Indian Shares Seen Muted on Fed Rates Confusion; Sun Pharma Wins Brazil Approval

Sun Pharma to Buy Organon for More Than $11 Billion

FAQ